Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.

Chuan Qin; Dai-Shi Tian; Luo-Qi Zhou; Ke Shang; Liang Huang; Ming-Hao Dong; Yun-Fan You; Jun Xiao; Ying Xiong; Wen Wang; Hao Pang; Jing-Jing Guo; Song-Bai Cai; Di Wang; Chun-Rui Li; Min Zhang; Bi-Tao Bu; Wei Wang

Originally published in Signal transduction and targeted therapy · 2023-01-04

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) have great potentials in autoimmune diseases and could be novel therapeutics for relapsed/refractory neuromyelitis optica spectrum disorder (NMOSD). To evaluate the safety and efficacy of the CT103A, a self-developed BCMA-targeting CAR construct against BCMA, in patients with AQP4-IgG seropositive NMOSD, an ongoing, investigator-initiated, open-label, single-arm, phase 1 clinical trial is conducted at our center. In total, 12 patients were administered with a CAR-BCMA infusion. Ten of the 12 patients dosed were women (83.3%), with a median age of 49.5 years (range, 30-67). were The most common events of grade 3 or higher were hematologic toxic effects. Seven patients (58%) developed infections, but no grade 4 infections occurred. Cytokine release syndrome was reported in all patients with only events of grade 1 or 2 observed. During the follow-up of a median 5.5 months, 11 patients had no relapse; all patients generally reported improvement in disabilities and quality-of-life outcomes; 11 patients' AQP-4 antibodies in serum showed a downward trend by the cutoff date.

Discussion

In this ongoing phase 1, first-in-human clinical study of CT103A, CAR T-cell therapy targeting BCMA, in relapsed or refractory AQP4-IgG seropositive NMOSD, patients displayed a manageable safety profile and had a promising clinical response without any additional immunosuppressive therapy.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?